Entera Bio Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Entera Bio Ltd., a foreign private issuer, for the month of September 2018. The report, dated September 21, 2018, incorporates by reference a press release regarding a key executive appointment.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance updates rather than financial performance.
Material Changes
The primary material change disclosed is the appointment of Dr. Arthur Santora as the company's Chief Medical Officer.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. The document serves solely to announce the leadership change.
Key Facts for Investors to Verify
- Dr. Arthur Santora has been appointed as Chief Medical Officer.
- The appointment was announced via press release on September 21, 2018.
- No financial data or operational metrics are included in this specific filing.